Data updated: Jun 28, 2026
Hodgkin Lymphoma Clinical Trial Landscape
Hodgkin Lymphoma is being studied across 479 clinical trials registered since 2008, with 160 programs currently active. The competitive pipeline includes 13 active Phase 3 trials, 113 active Phase 2 trials, and 31 active Phase 1 trials.
Top industry sponsors include Merck, Takeda, Tessa Therapeutics.
Trial activity
160 active / 479 total since 2008
Active by phase 13 Ph3 / 36 113 Ph2 / 302 31 Ph1 / 137 3 Ph4 / 4
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Merck 3 8 0
Takeda 2 2 0
Tessa Therapeutics 2 0 0
AstraZeneca 1 1 0
Akeso 1 1 0
Compass Therapeutics 1 0 0
FBD Biologics Limited 1 0 0
VIVUS LLC 1 0 0
MacroGenics 1 0 0
GSK 1 0 0
Immunitas Therapeutics 1 0 0
Marker Therapeutics, Inc. 1 0 0
Bio-Path Holdings, Inc. 1 0 0
Checkpoint Therapeutics, Inc. 1 0 0
Innolake Biopharm 1 0 0
All 15 active Hodgkin Lymphoma sponsors
Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.
Unlock with ProHow the field has grown
New-trial starts peaked in 2017 (35 registered); 2025 saw 18. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (18 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 30
2017 35
2018 29
2019 24
2020 18
2021 20
2022 27
2023 18
2024 29
2025 18
2026 16
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (2) 902
2017 (2) 333
2018 (0) 0
2019 (1) 994
2020 (3) 299
2021 (0) 0
2022 (3) 130
2023 (2) 1,030
2024 (3) 96
2025 (0) 0
2026 (2) 446
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07572123 NOT YET RECRUITING
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI) n=374
NCT05675410 RECRUITING
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI) n=1,875
NCT02166463 ACTIVE NOT RECRUITING
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
National Cancer Institute (NCI) n=600
NCT03907488 ACTIVE NOT RECRUITING
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI) n=994
NCT04685616 RECRUITING
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
University College, London n=1,042
NCT06563245 RECRUITING
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Children's Cancer Group, China n=96
NCT07256158 NOT YET RECRUITING
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS n=518
NCT04459416 ACTIVE NOT RECRUITING
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center n=299
NCT05595447 RECRUITING
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Hospital Regional de Alta Especialidad del Bajio n=20
NCT06170489 RECRUITING
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Shanghai Junshi Bioscience Co., Ltd. n=185
NCT04638790 RECRUITING
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia n=300
NCT06465446 NOT YET RECRUITING
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. n=202
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT02684708 COMPLETED
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
University of Giessen n=2,921
NCT07450508 COMPLETED
Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma
Cairo University n=88
NCT04486391 TERMINATED
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
BeiGene n=3
NCT01712490 COMPLETED
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda n=1,334
NCT02684292 COMPLETED
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Merck Sharp & Dohme LLC n=304
NCT01358747 COMPLETED
Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL
Centre Hospitalier Universitaire Dijon
NCT03159897 COMPLETED
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS n=500
NCT05181540 TERMINATED
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Angiocrine Bioscience n=130
NCT05711628 WITHDRAWN
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01026220 COMPLETED
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Children's Oncology Group n=166
NCT02566395 COMPLETED
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health n=10
NCT01597778 COMPLETED
Double Cord Versus Haploidentical (BMT CTN 1101)
Medical College of Wisconsin n=368
NCT00992030 TERMINATED
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Fondazione Michelangelo n=112
NCT01652261 WITHDRAWN
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)
European Organisation for Research and Treatment of Cancer - EORTC
NCT01987596 TERMINATED
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Barbara Ann Karmanos Cancer Institute n=23
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT00928018 COMPLETED
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Dana-Farber Cancer Institute n=139
NCT00784537 COMPLETED
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
Fondazione Italiana Linfomi - ETS n=520
NCT01034163 COMPLETED
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
Novartis Pharmaceuticals n=41
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT01896999 ACTIVE NOT RECRUITING
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01703949 ACTIVE NOT RECRUITING
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
NCT03179917 ACTIVE NOT RECRUITING
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT07576725 NOT YET RECRUITING
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
NCT05723055 ACTIVE NOT RECRUITING
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
University of Utah
NCT07164469 NOT YET RECRUITING
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT05092451 RECRUITING
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT01920932 ACTIVE NOT RECRUITING
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
St. Jude Children's Research Hospital
NCT07566377 RECRUITING
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT02332668 RECRUITING
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
NCT03057795 ACTIVE NOT RECRUITING
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
City of Hope Medical Center
NCT05949931 RECRUITING
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Sun Yat-sen University
NCT06812858 RECRUITING
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
St. Petersburg State Pavlov Medical University
NCT07551583 NOT YET RECRUITING
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
NCT00840047 ACTIVE NOT RECRUITING
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
NCT06377566 RECRUITING
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT07275216 RECRUITING
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
City of Hope Medical Center
NCT03755804 ACTIVE NOT RECRUITING
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
NCT06137144 RECRUITING
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
AstraZeneca
NCT03618550 RECRUITING
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03418038 RECRUITING
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
NCT05355051 RECRUITING
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT05922904 ACTIVE NOT RECRUITING
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT06617286 NOT YET RECRUITING
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
New York Medical College
NCT04491370 RECRUITING
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
New York Medical College
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT07234487 RECRUITING
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
St. Petersburg State Pavlov Medical University
NCT06915246 RECRUITING
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
NCT07021989 NOT YET RECRUITING
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Michael Spinner, MD
NCT05615636 RECRUITING
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT03681561 RECRUITING
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Veronika Bachanova
NCT05502250 ACTIVE NOT RECRUITING
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT06745076 RECRUITING
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
University of Washington
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT03407144 ACTIVE NOT RECRUITING
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Merck Sharp & Dohme LLC
NCT02940301 ACTIVE NOT RECRUITING
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
NCT03033914 ACTIVE NOT RECRUITING
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT06484920 RECRUITING
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Rita Assi
NCT06504394 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Merck Sharp & Dohme LLC
NCT04938232 ACTIVE NOT RECRUITING
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Dana-Farber Cancer Institute
NCT04067037 ACTIVE NOT RECRUITING
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Henan Cancer Hospital
NCT05180097 RECRUITING
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Canadian Cancer Trials Group
NCT05300282 RECRUITING
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Fondazione Italiana Linfomi - ETS
NCT03674411 ACTIVE NOT RECRUITING
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT06393361 RECRUITING
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Chinese PLA General Hospital
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00846742 ACTIVE NOT RECRUITING
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
St. Jude Children's Research Hospital
NCT05977673 RECRUITING
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
Fondazione Italiana Linfomi - ETS
NCT04871607 RECRUITING
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
City of Hope Medical Center
NCT07188090 RECRUITING
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University
NCT06984146 RECRUITING
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT06521567 ACTIVE NOT RECRUITING
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT02979522 ACTIVE NOT RECRUITING
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
NCT03125642 RECRUITING
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
NCT03016871 ACTIVE NOT RECRUITING
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
City of Hope Medical Center
NCT06090864 RECRUITING
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
UNC Lineberger Comprehensive Cancer Center
NCT05565417 ACTIVE NOT RECRUITING
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT07209059 RECRUITING
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
National Research Center for Hematology, Russia
NCT03233347 ACTIVE NOT RECRUITING
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Academic and Community Cancer Research United
NCT04561206 RECRUITING
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
City of Hope Medical Center
NCT02758717 ACTIVE NOT RECRUITING
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Academic and Community Cancer Research United
NCT05039073 RECRUITING
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Emory University
NCT03517137 ACTIVE NOT RECRUITING
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
European Organisation for Research and Treatment of Cancer - EORTC
NCT04099966 RECRUITING
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
NCT04961515 RECRUITING
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06164275 ACTIVE NOT RECRUITING
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
Northwestern University
NCT03739502 RECRUITING
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT06377540 RECRUITING
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Masonic Cancer Center, University of Minnesota
NCT05253495 RECRUITING
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
New York Medical College
NCT03697408 ACTIVE NOT RECRUITING
Itacitinib + Everolimus in Hodgkin Lymphoma
University of Pennsylvania
NCT02797470 ACTIVE NOT RECRUITING
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
AIDS Malignancy Consortium
NCT06931613 ENROLLING BY INVITATION
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
St. Petersburg State Pavlov Medical University
NCT06919679 NOT YET RECRUITING
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
University of Cologne
NCT06916416 NOT YET RECRUITING
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
University of Cologne
NCT06045195 NOT YET RECRUITING
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
University of Cologne
NCT03480334 ACTIVE NOT RECRUITING
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
University of Cologne
NCT04788043 ACTIVE NOT RECRUITING
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Stanford University
NCT06848569 RECRUITING
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
Sun Yat-sen University
NCT06299462 RECRUITING
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT06642792 RECRUITING
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Akeso
NCT06684509 NOT YET RECRUITING
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
Assiut University
NCT03712202 ACTIVE NOT RECRUITING
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
NCT04838652 RECRUITING
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
University of Cologne
NCT06563778 NOT YET RECRUITING
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Chinese PLA General Hospital
NCT04837859 RECRUITING
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
University of Cologne
NCT05404945 ACTIVE NOT RECRUITING
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
University of Virginia
NCT05955105 RECRUITING
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
NCT03337919 ACTIVE NOT RECRUITING
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
University College, London
NCT04510636 RECRUITING
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
University Health Network, Toronto
NCT04378647 RECRUITING
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT06190067 RECRUITING
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Navy General Hospital, Beijing
NCT05627115 NOT YET RECRUITING
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
University College, London
NCT05900765 RECRUITING
A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma
Sun Yat-sen University
NCT05896046 RECRUITING
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
NCT04268706 ACTIVE NOT RECRUITING
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Tessa Therapeutics
NCT04935684 RECRUITING
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
NCT05683704 ENROLLING BY INVITATION
Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
Tianjin Medical University Cancer Institute and Hospital
NCT03852407 RECRUITING
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT04866654 RECRUITING
Radiation Free Chemotherapy for Early Hodgkin Lymphoma
Medical University of Gdansk
NCT02259556 RECRUITING
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Chinese PLA General Hospital
NCT07641010 NOT YET RECRUITING
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
Shanghai Jiao Tong University School of Medicine
NCT02362035 COMPLETED
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Acerta Pharma BV
NCT03580564 COMPLETED
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05337735 SUSPENDED
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
NCT01384513 COMPLETED
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03213665 COMPLETED
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT02213913 COMPLETED
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
NCT03652441 COMPLETED
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
University of Cologne
NCT05255601 TERMINATED
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Bristol-Myers Squibb
NCT02362997 COMPLETED
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
NCT03598608 COMPLETED
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Merck Sharp & Dohme LLC
NCT05508867 COMPLETED
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Merck Sharp & Dohme LLC
NCT05179603 TERMINATED
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT02227199 COMPLETED
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
University of Washington
NCT01760655 COMPLETED
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04875195 COMPLETED
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Merck Sharp & Dohme LLC
NCT01592370 COMPLETED
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
NCT01508312 COMPLETED
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04074746 COMPLETED
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
NCT02356159 COMPLETED
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT06018129 TERMINATED
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Genmab
NCT04318080 COMPLETED
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
BeiGene
NCT03646123 TERMINATED
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
NCT05883449 TERMINATED
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Affimed GmbH
NCT01771107 COMPLETED
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT03739619 COMPLETED
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Emory University
NCT03331341 COMPLETED
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
NCT05011058 TERMINATED
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Viracta Therapeutics, Inc.
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT05008224 COMPLETED
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
Merck Sharp & Dohme LLC
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT01350258 TERMINATED
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01532635 TERMINATED
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03434730 COMPLETED
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT03615105 TERMINATED
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
NCT03004833 COMPLETED
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
University of Cologne
NCT02744612 COMPLETED
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01701986 COMPLETED
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT03190174 COMPLETED
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
NCT02824029 COMPLETED
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT02927769 COMPLETED
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Bristol-Myers Squibb
NCT03209973 COMPLETED
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
BeiGene
NCT03615664 COMPLETED
The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
Polish Lymphoma Research Group
NCT02453594 COMPLETED
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Merck Sharp & Dohme LLC
NCT02191930 COMPLETED
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
University of Cologne
NCT01998035 TERMINATED
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
NCT02295722 TERMINATED
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
AHS Cancer Control Alberta
NCT01716806 COMPLETED
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
NCT01492088 COMPLETED
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Millennium Pharmaceuticals, Inc.
NCT02624388 TERMINATED
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
University of Virginia
NCT01597219 COMPLETED
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
University College, London
NCT03722147 COMPLETED
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma
Akeso
NCT04052997 COMPLETED
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
ADC Therapeutics S.A.
NCT04478123 COMPLETED
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Memorial Sloan Kettering Cancer Center
NCT03155425 COMPLETED
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
NCT03495713 TERMINATED
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Abramson Cancer Center at Penn Medicine
NCT01858922 COMPLETED
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Baylor College of Medicine
NCT03128359 COMPLETED
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT03734601 COMPLETED
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03436862 COMPLETED
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
SCRI Development Innovations, LLC
NCT02181738 COMPLETED
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
Bristol-Myers Squibb
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT02869633 COMPLETED
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
NCT02304458 COMPLETED
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT03947255 TERMINATED
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Seagen Inc.
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT04091490 COMPLETED
Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
NCT01203020 COMPLETED
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
West Virginia University
NCT03776864 TERMINATED
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
University of Washington
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT01028716 TERMINATED
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT01947140 COMPLETED
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT02572167 COMPLETED
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Seagen Inc.
NCT03505996 COMPLETED
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
CStone Pharmaceuticals
NCT01030900 COMPLETED
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Cancer Institute (NCI)
NCT02292979 COMPLETED
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
The Lymphoma Academic Research Organisation
NCT03580408 COMPLETED
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
NCT04138875 WITHDRAWN
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
NCT02429375 COMPLETED
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT02686346 COMPLETED
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
The Lymphoma Academic Research Organisation
NCT01535924 COMPLETED
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Beth Christian
NCT01780662 COMPLETED
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01468311 TERMINATED
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
National Cancer Institute (NCI)
NCT01805037 TERMINATED
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
NCT00742027 COMPLETED
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Novartis Pharmaceuticals
NCT02298283 COMPLETED
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
The Lymphoma Academic Research Organisation
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT02424968 COMPLETED
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT01018979 COMPLETED
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
NCT00792467 COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Italfarmaco
NCT02104427 COMPLETED
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
GPCR Therapeutics, Inc.
NCT02626884 COMPLETED
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
University of Cologne
NCT02939014 COMPLETED
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Takeda
NCT02414568 COMPLETED
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
The Lymphoma Academic Research Organisation
NCT02059239 COMPLETED
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Weill Medical College of Cornell University
NCT04373083 WITHDRAWN
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Regeneron Pharmaceuticals
NCT01169636 COMPLETED
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT02227433 COMPLETED
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.
Fondazione Italiana Linfomi - ETS
NCT00670592 COMPLETED
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
Novartis Pharmaceuticals
NCT03739606 WITHDRAWN
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
NCT01121120 TERMINATED
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Tarix Pharmaceuticals
NCT03114683 COMPLETED
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
NCT02321592 COMPLETED
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
University of Cologne
NCT01258998 COMPLETED
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT01075321 COMPLETED
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT02505269 COMPLETED
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
NCT02875067 TERMINATED
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NYU Langone Health
NCT01921387 COMPLETED
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Fred Hutchinson Cancer Center
NCT01657331 COMPLETED
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Columbia University
NCT01217229 COMPLETED
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Daiichi Sankyo
NCT03343652 COMPLETED
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma
St. Petersburg State Pavlov Medical University
NCT00967369 COMPLETED
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
M.D. Anderson Cancer Center
NCT00918333 COMPLETED
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT00654732 COMPLETED
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
NCT00789776 COMPLETED
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT03343665 COMPLETED
Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma
St. Petersburg State Pavlov Medical University
NCT01527045 COMPLETED
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00723099 COMPLETED
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT01326702 COMPLETED
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01251575 COMPLETED
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03120676 TERMINATED
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01453504 COMPLETED
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
University of Cologne
NCT00866333 TERMINATED
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
Syndax Pharmaceuticals
NCT01076543 COMPLETED
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01529827 COMPLETED
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
NCT01964755 TERMINATED
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
NCT01839916 COMPLETED
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01159067 TERMINATED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
NCT01008462 COMPLETED
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
NCT02243436 COMPLETED
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT02763254 TERMINATED
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
Cell Medica Ltd
NCT01874054 COMPLETED
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
NCT01408563 COMPLETED
Reduced Intensity Double Umbilical Cord Blood Transplantation
Massachusetts General Hospital
NCT02208037 COMPLETED
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
NCT01165112 COMPLETED
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
University of Washington
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT01393106 COMPLETED
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Gilead Sciences
NCT00709592 COMPLETED
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Virginia Commonwealth University
NCT01965119 COMPLETED
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma
Samsung Medical Center
NCT01569204 COMPLETED
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
NCT00896454 COMPLETED
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT01273766 COMPLETED
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT01877005 COMPLETED
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
The Lymphoma Academic Research Organisation
NCT01789255 COMPLETED
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
NCT01745913 TERMINATED
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
NCT02567851 COMPLETED
A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity
University of Birmingham
NCT00984165 TERMINATED
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT01393717 COMPLETED
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
City of Hope Medical Center
NCT01534078 COMPLETED
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
NCT01969435 COMPLETED
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Washington University School of Medicine
NCT02247869 COMPLETED
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS
NCT02244021 COMPLETED
BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV
Fondazione Italiana Linfomi - ETS
NCT02456675 TERMINATED
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
Incyte Corporation
NCT00867529 COMPLETED
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
NCT01343368 TERMINATED
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT01460940 COMPLETED
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
NCT00722865 TERMINATED
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma
Massachusetts General Hospital
NCT02408042 WITHDRAWN
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
NCT01158118 COMPLETED
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
NCT01110135 COMPLETED
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
NCT00795769 COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01427881 COMPLETED
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
NCT00733824 COMPLETED
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Washington University School of Medicine
NCT02115126 WITHDRAWN
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant
David Rizzieri, MD
NCT01699581 TERMINATED
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
Greg Monohan
NCT01523847 COMPLETED
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
Fondazione Italiana Linfomi - ETS
NCT01652014 WITHDRAWN
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
University of Medicine and Dentistry of New Jersey
NCT01022996 COMPLETED
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Novartis Pharmaceuticals
NCT01195766 COMPLETED
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
NCT00916045 TERMINATED
Pilot Study of Unrelated Cord Blood Transplantation
King's College Hospital NHS Trust
NCT00724984 COMPLETED
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Pharmacyclics LLC.
NCT01263899 COMPLETED
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
S*BIO
NCT00636311 COMPLETED
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
Istituto Clinico Humanitas
NCT01476410 COMPLETED
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
NCT04758650 TERMINATED
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Universitair Ziekenhuis Brussel
NCT05272384 RECRUITING
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
NCT07575893 NOT YET RECRUITING
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
New York Medical College
NCT07444632 RECRUITING
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT06150664 RECRUITING
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT06487624 RECRUITING
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
FBD Biologics Limited
NCT06176690 RECRUITING
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Baylor College of Medicine
NCT05544968 RECRUITING
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
NCT07020533 RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT02287311 ACTIVE NOT RECRUITING
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Baylor College of Medicine
NCT01192464 ACTIVE NOT RECRUITING
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Baylor College of Medicine
NCT05362773 RECRUITING
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT04664179 RECRUITING
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Baylor College of Medicine
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT02508038 RECRUITING
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT06383338 RECRUITING
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
Murdoch Childrens Research Institute
NCT03150329 ACTIVE NOT RECRUITING
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
NCT05798897 RECRUITING
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Marker Therapeutics, Inc.
NCT02917083 RECRUITING
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
NCT04288726 RECRUITING
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT03843294 ACTIVE NOT RECRUITING
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Catherine Bollard
NCT05162976 ACTIVE NOT RECRUITING
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
City of Hope Medical Center
NCT01333046 ACTIVE NOT RECRUITING
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Baylor College of Medicine
NCT02663297 ACTIVE NOT RECRUITING
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT04072458 ACTIVE NOT RECRUITING
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings, Inc.
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT05476770 RECRUITING
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT06494371 RECRUITING
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Ruijin Hospital
NCT05352828 ACTIVE NOT RECRUITING
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Tessa Therapeutics
NCT06254495 TERMINATED
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT06870487 TERMINATED
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT05605119 TERMINATED
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Aurigene Discovery Technologies Limited
NCT03236935 COMPLETED
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT04681105 COMPLETED
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
NCT06120504 TERMINATED
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT02408861 TERMINATED
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT04640779 COMPLETED
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT05065866 COMPLETED
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT03259503 COMPLETED
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT05216835 COMPLETED
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
AstraZeneca
NCT03432741 TERMINATED
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
NCT03755414 COMPLETED
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT01476839 COMPLETED
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
City of Hope Medical Center
NCT03524235 COMPLETED
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Noah Merin
NCT02595866 COMPLETED
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
NCT02576496 COMPLETED
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Mundipharma Research Limited
NCT03198234 TERMINATED
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Roncarolo, Maria Grazia, MD
NCT01588015 COMPLETED
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT03013933 COMPLETED
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
NCT02168140 COMPLETED
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT01523223 COMPLETED
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Robert Lowsky
NCT04952584 WITHDRAWN
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
NCT01316146 WITHDRAWN
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
UNC Lineberger Comprehensive Cancer Center
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03302728 COMPLETED
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Peter MacCallum Cancer Centre, Australia
NCT03925935 COMPLETED
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
Angiocrine Bioscience
NCT02613598 COMPLETED
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
NCT03018223 COMPLETED
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
NCT01767766 COMPLETED
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
TG Therapeutics, Inc.
NCT01953692 COMPLETED
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Merck Sharp & Dohme LLC
NCT02973113 COMPLETED
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Baylor College of Medicine
NCT02432235 COMPLETED
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
ADC Therapeutics S.A.
NCT03730363 COMPLETED
Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma
Reinhold Munker
NCT01822509 COMPLETED
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT03885947 COMPLETED
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Alla Keyzner
NCT02129582 COMPLETED
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT04292626 COMPLETED
Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT01207921 COMPLETED
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma
Washington University School of Medicine
NCT01643603 TERMINATED
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
NCT01572519 COMPLETED
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Janssen Research & Development, LLC
NCT02181218 COMPLETED
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
NCT01943682 COMPLETED
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT00860171 TERMINATED
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
NCT01609816 TERMINATED
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
NCT01742793 TERMINATED
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Yale University
NCT01447056 COMPLETED
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Baylor College of Medicine
NCT03471351 TERMINATED
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Rhizen Pharmaceuticals SA
NCT02254239 TERMINATED
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Mayo Clinic
NCT02164006 COMPLETED
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
TG Therapeutics, Inc.
NCT02665650 COMPLETED
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Affimed GmbH
NCT01897012 COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
NCT01634217 COMPLETED
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
NCT02240719 COMPLETED
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
NCT02378922 WITHDRAWN
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Fred Hutchinson Cancer Center
NCT02343666 WITHDRAWN
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Fred Hutchinson Cancer Center
NCT01342289 COMPLETED
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03107663 COMPLETED
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
ImaginAb, Inc.
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT00779584 COMPLETED
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)
Merck Sharp & Dohme LLC
NCT01484015 COMPLETED
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
NCT01129193 COMPLETED
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Amir Mortazavi
NCT01567709 COMPLETED
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
NCT00909948 TERMINATED
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Massachusetts General Hospital
NCT01056679 COMPLETED
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
University of Cologne
NCT01460134 COMPLETED
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Celldex Therapeutics
NCT03205891 WITHDRAWN
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
NCT01929941 TERMINATED
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Incyte Corporation
NCT01900509 COMPLETED
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
NCT01032148 TERMINATED
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
NCT01555853 TERMINATED
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Washington University School of Medicine
NCT01745354 TERMINATED
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Robert Lowsky
NCT00901069 COMPLETED
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Shams Shakil
NCT01950364 COMPLETED
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.
NCT01748721 COMPLETED
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Morphotek
NCT01902160 COMPLETED
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT01658319 COMPLETED
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01908387 TERMINATED
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene Corporation
NCT00608361 COMPLETED
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00963495 TERMINATED
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
University Health Network, Toronto
NCT01158274 COMPLETED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01088763 TERMINATED
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
NCT00933985 TERMINATED
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
NCT01231919 COMPLETED
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT00791011 COMPLETED
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Amgen
NCT00769288 COMPLETED
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00722488 COMPLETED
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
Millennium Pharmaceuticals, Inc.
NCT00871702 COMPLETED
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Washington University School of Medicine
NCT00994500 COMPLETED
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
NCT01149668 COMPLETED
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics LLC.
NCT00741871 COMPLETED
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
S*BIO
NCT01452334 WITHDRAWN
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
Bristol-Myers Squibb
NCT01116154 TERMINATED
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT04726501 ACTIVE NOT RECRUITING
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
Children's Cancer Group, China
NCT06831370 RECRUITING
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
NCT06761911 NOT YET RECRUITING
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Xiuhua Sun
NCT01990534 COMPLETED
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Millennium Pharmaceuticals, Inc.
Full Hodgkin Lymphoma Pipeline
Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only